Pediatric Preclinical Testing Program (PPTP) stage 2 testing of the Aurora A kinase inhibitor MLN8237

被引：0
|
作者：
Smith, M. A. [2 ]
Houghton, P. J. [1 ]
Morton, C. L. [1 ]
Maris, J. M. [3 ]
Courtright, J. [3 ]
Carol, H. [4 ]
Lock, R. B. [4 ]
Yang, Y.
Manfredi, M. G.
机构：
[1] St Jude Childrens Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA
[2] NCI, Canc Therapy Evaluat Program, Bethesda, MD 20892 USA
[3] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA
[4] Childrens Canc Inst Australia, Leukaemia Biol Program, Randwick, NSW, Australia
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(08)72220-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：92 / 93
页数：2
相关论文
共 50 条
  • [41] Anovel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma
    Goerguen, Guellue
    Calabrese, Elisabetta
    Hideshima, Teru
    Ecsedy, Jeffrey
    Perrone, Giulia
    Mani, Mala
    Ikeda, Hiroshi
    Bianchi, Giada
    Hu, Yiguo
    Cirstea, Diana
    Santo, Loredana
    Tai, Yu-Tzu
    Nahar, Sabikun
    Zheng, Mei
    Bandi, Madhavi
    Carrasco, Ruben D.
    Raje, Noopur
    Munshi, Nikhil
    Richardson, Paul
    Anderson, Kenneth C.
    BLOOD, 2010, 115 (25) : 5202 - 5213
  • [42] The Pediatric Preclinical Testing Program (PPTP): Analysis of the first 10 years in vivo testing
    Houghton, P.
    Lock, R.
    Carol, H.
    Gorlick, R.
    Kolb, A.
    Maris, J.
    Keir, S.
    Wu, J.
    Kang, M.
    Reynolds, P.
    Kurmasheva, R.
    Smith, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : 131 - 132
  • [43] Initial testing (stage 1) of the mTOR kinase inhibitor AZD8055 by the pediatric preclinical testing program
    Houghton, Peter J.
    Gorlick, Richard
    Kolb, E. Anders
    Lock, Richard
    Carol, Hernan
    Morton, Christopher L.
    Keir, Stephen T.
    Reynolds, C. Patrick
    Kang, Min H.
    Phelps, Doris
    Maris, John M.
    Billups, Catherine
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2012, 58 (02) : 191 - 199
  • [44] Initial Testing (Stage 1) of the Multi-Targeted Kinase Inhibitor Sorafenib by the Pediatric Preclinical Testing Program
    Keir, Stephen T.
    Maris, John M.
    Lock, Richard
    Kolb, E. Anders
    Gorlick, Richard
    Carol, Hernan
    Morton, Christopher L.
    Reynolds, C. Patrick
    Kang, Min H.
    Watkins, Amy
    Houghton, Peter J.
    Smith, Malcolm A.
    PEDIATRIC BLOOD & CANCER, 2010, 55 (06) : 1126 - 1133
  • [45] Pediatric preclinical testing program (PPTP) evaluation of the KSP inhibitor ispinesib (SB-715992)
    Houghton, P. J.
    Maris, J. M.
    Friedman, H. S.
    Keir, S. T.
    Lock, R. B.
    Gorlick, R.
    Kolb, E. A.
    Reynolds, C. P.
    Morton, C.
    Smith, M. A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 98 - 98
  • [46] Development of a phase 2 study of the aurora kinase-A inhibitor alisertib (MLN8237) in pretreated patients (pts) with urothelial cancer (UC).
    Necchi, Andrea
    Mariani, Luigi
    Giannatempo, Patrizia
    Raggi, Daniele
    Fare, Elena
    Marchlano, Alfonso
    Crippa, Flavlo
    Togllardi, Elena
    Daldone, Maria Grazla
    Gianni, Alessandro M.
    Salvioni, Roberto
    De Braud, Filippo G.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [47] Effects of alisertib (MLN8237), an investigational Aurora A kinase inhibitor (AAKi), on the QTc interval in patients (pts) with advanced malignancies
    Zhou, X.
    Nemunaitis, J.
    Pant, S.
    Bauer, T. M.
    Patel, M.
    Sarantopoulos, J.
    Lockhart, A. C.
    Goodman, D.
    Zhang, B.
    Ullmann, C. Dansky
    Mould, D. R.
    Venkatakrishnan, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S76 - S77
  • [48] Phase I study of the investigational drug MLN8237, an Aurora a kinase (AAK) inhibitor, in patients (pts) with solid tumors
    Dees, E. C.
    Infante, J. R.
    Burris, H. A.
    Astsaturov, I. A.
    Stinchcombe, T.
    Liu, H.
    Galvin, K.
    Venkatakrishnan, K.
    Fingert, H. J.
    Cohen, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] The Aurora A Kinase Inhibitor MLN8237 Significantly Enhances the Antitumor Activity of Oncolytic Measles Virus Derivatives in the Treatment of Glioblastoma
    Allen, Cory
    Iankov, Ianko
    Opyrchal, Mateusz
    Keith, Lucas A. G.
    Schroeder, Mark A.
    Sarkaria, Jann N.
    Ecsedy, Jeffrey
    Galanis, Evanthia
    MOLECULAR THERAPY, 2012, 20 : S166 - S166
  • [50] The novel Aurora A kinase inhibitor MLN8237 is active in resistant chronic myeloid leukaemia and significantly increases the efficacy of nilotinib
    Kelly, Kevin R.
    Ecsedy, Jeffrey
    Medina, Ernest
    Mahalingam, Devalingam
    Padmanabhan, Swaminathan
    Nawrocki, Steffan T.
    Giles, Francis J.
    Carew, Jennifer S.
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2011, 15 (10) : 2057 - 2070
12345